Ridloff Elena 4
4 · Kymera Therapeutics, Inc. · Filed Jun 3, 2025
Insider Transaction Report
Form 4
Ridloff Elena
Director
Transactions
- Sale
Common Stock
2025-06-03$45.50/sh−7,200$327,600→ 4,800 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-03−12,000→ 0 totalExercise: $27.67Exp: 2033-06-15→ Common Stock (12,000 underlying) - Exercise/Conversion
Common Stock
2025-06-03$27.67/sh+12,000$332,040→ 12,000 total - Sale
Common Stock
2025-06-03$47.00/sh−4,800$225,600→ 0 total
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person.
- [F2]The shares underlying this stock option are fully vested and exercisable.